Deltex Medical Group plc
DTXMF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.08 | 0.01 | -0.14 |
| FCF Yield | -1.21% | -9.67% | -59.89% | -12.32% |
| EV / EBITDA | -15.64 | -15.27 | -23.71 | -44.39 |
| Quality | ||||
| ROIC | -32.28% | -9.31% | -7.37% | -11.96% |
| Gross Margin | 69.25% | 66.82% | 9.90% | 66.86% |
| Cash Conversion Ratio | 0.04 | 0.80 | 1.24 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | -19.48% | -21.72% | -24.91% | -22.46% |
| Free Cash Flow Growth | 87.36% | 57.27% | -86.11% | -57.18% |
| Safety | ||||
| Net Debt / EBITDA | -4.38 | -4.11 | -9.89 | -14.89 |
| Interest Coverage | 0.00 | -4.25 | -3.61 | -4.59 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.54 | 0.45 | 0.43 |
| Cash Conversion Cycle | 133.18 | 137.67 | 196.24 | 94.83 |